Skip to Main Content
Skip Nav Destination

The misregulation of protein arginine methyltransferases (PRMTs) has been implicated in cancer and other diseases. There are nine PRMTs and small molecule inhibitors have been developed that selectively target most of the family members. These inhibitors have progressed from the chemical probe stage, where they have played a role in dissecting out PRMT-related mechanistic pathways and have been used in pre-clinical in vivo settings, to the development of drugs that are currently being leveraged in clinical trials. Here we will discuss the evolution of this field.

You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal